TL;DR: The SAFER Banking Act — the cannabis industry’s most consequential pending financial legislation — is gaining renewed momentum in the 119th Congress as the DEA’s Schedule III administrative hearing nears its final evidentiary phase. With rescheduling expected to resolve the fundamental federal conflict over cannabis commerce, banking access reform is emerging as the logical parallel track: a bill that could move faster than full legalization and deliver immediate, measurable relief to multi-state operators, licensed dispensaries, and cannabis-adjacent businesses currently locked out of conventional financial services.
Market Analysis
The cost of operating without banking access remains one of the single largest structural headwinds facing U.S. cannabis operators. Multi-state operators (MSOs) currently classified under Schedule I face a compounding disadvantage: they cannot use federal banking infrastructure, they pay elevated rates to state-chartered institutions willing to accept cannabis deposits under program agreements, and they absorb cash handling costs that would be negligible for any other retail or consumer goods business of comparable scale.
For publicly traded cannabis companies, these costs flow directly into operating expenses and erode the free cash flow generation that institutional investors use to value cannabis equities. Green Thumb Industries, Trulieve, Curaleaf, and their peers have built sophisticated treasury management systems to navigate the cash-heavy operating environment — but those systems represent capital expenditures and overhead that a post-SAFER world would eliminate. Analysts modeling normalized earnings for MSOs under banking access consistently arrive at EBITDA margin expansion estimates of 150 to 300 basis points on the low end, with more optimistic models citing even greater uplift from reduced cash handling and insurance premium normalization.
The capital markets dimension is equally consequential. Cannabis companies currently raise equity capital at a significant premium to cost — retail investor bases, limited institutional participation, and the reputational constraints that prevent large asset managers from taking positions in Schedule I businesses all contribute to an elevated cost of capital that suppresses reinvestment rates and slows capacity expansion. SAFER Banking passage would not immediately eliminate all of these constraints, but it would signal to the institutional community that Congress has formally de-risked cannabis commerce, accelerating the sector’s inclusion in mainstream financial indices and fund mandates. Monitor current equity positions in this space through our cannabis stock tracker.
Regulatory and Market Context
The SAFER Banking Act — the Senate’s updated iteration of the House-passed SAFE Banking Act — has been through multiple Congress cycles without achieving final passage. The central impediment has historically been Senate floor scheduling, with competing priorities and the absence of bipartisan consensus on whether banking access should be packaged with broader cannabis reform or advanced as a standalone financial services measure.
The rescheduling dynamic changes that calculus materially. Under Schedule III, the primary legal rationale for banking refusal shifts: financial institutions have cited Controlled Substances Act exposure as the reason for declining cannabis accounts. A Schedule III designation does not create full federal legality, but it meaningfully alters the enforcement risk profile for banks and credit unions considering cannabis business relationships. Several legal scholars and banking law analysts have concluded that Schedule III rescheduling alone — without explicit SAFER Banking passage — could prompt many financial institutions to voluntarily extend services to cannabis operators under existing compliance frameworks.
That interpretation, if broadly adopted, would reduce the political urgency for SAFER Banking as a standalone bill — but it would not eliminate the need entirely. Explicit statutory language creating a safe harbor for financial institutions would provide the regulatory certainty that risk-averse compliance departments require. The Federal Reserve, OCC, and FDIC have signaled informally that they would welcome legislative clarity rather than relying on enforcement discretion guidance.
Congressional floor timing remains the wildcard. The Senate Banking Committee has held SAFER Banking hearings and markup sessions, and the bill has bipartisan co-sponsors — a rare characteristic in the current legislative environment. The question is whether Senate leadership chooses to advance it as a standalone measure, attach it to a larger financial services or appropriations vehicle, or defer until the Schedule III rulemaking process reaches final disposition. Industry advocates are pressing for the standalone route on the argument that attaching it to larger legislation exposes it to unrelated conference risks.
Conclusion
SAFER Banking Act passage would represent the most immediate, tangible financial improvement for the cannabis sector short of federal legalization — and it may be more achievable on a near-term timeline than any other major cannabis reform measure. The combination of advancing Schedule III rescheduling and bipartisan support for banking access creates a legislative window that did not exist eighteen months ago.
For cannabis investors, the clearest expression of the banking access thesis is in free cash flow projections for MSOs over the next 12 to 24 months: models that incorporate normalized banking costs show materially higher enterprise value floors for established operators. Smaller licensed retailers and craft cannabis cultivators, currently the most exposed to cash handling costs as a percentage of revenue, would see the largest proportional benefit. The sector’s trajectory into the second half of 2026 will hinge on whether congressional momentum on this issue accelerates alongside the DEA hearing timeline — two parallel tracks that, if they converge, could redefine the cannabis investment thesis for the next cycle.